The Business Research Company’s Ophthalmology
Drugs global market report, covers the year-on-year growth of the global Ophthalmology Drugs market
historic and forecast growth. It also includes chapters on the Ophthalmology
Drugs
market trends, geographical analysis, and competitive landscape.
Order
the report at:
The global ophthalmology drugs market size is
expected to reach $36 billion by 2022, significantly
growing at a CAGR of
around 7% during the forecast period.
Ophthalmology
Drugs Market Trends
The
ophthalmology drugs market consists of sales of ophthalmology drugs and related
services by entities (organizations, sole traders and partnerships) that
produce ophthalmology drugs to treat eye related diseases. This industry
includes establishments that produce antiglaucoma drugs used to treat glaucoma
diseases, anti- inflammatory and tear stimulating drugs under dry eye
medications drugs, and other drugs for treating retinal disorders and
allergies.
Drug
manufacturers are developing new class of compounds called Rho-kinase
inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral
part of cellular functions such as contraction of vascular smooth muscle cells,
organization of the actin cytoskeleton, cell adhesion and motility and gene
expression. These inhibitors are different from widely used prostaglandin
analogs because they target the outflow through trabecular meshwork rather than
the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease
intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours,
which is more effective than the previous generation of drugs for this
condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535,
AR-12286, AR-13324, AMA0076 and BOL-303259-X.
The growth in the Ophthalmology Drugs market
is due to the expected rise in prevalence of eye conditions such as age-related
macular degeneration (AMD), diabetic retinopathy and glaucoma that require
ophthalmology drugs.
Download
a sample of the report:
The global Ophthalmology Drugs market report covers the
following regions under the geographical analysis section: Asia Pacific,
Western Europe, North America, Middle East, Africa, South America, and Eastern
Europe. Major countries under each of these regions are also covered under the
country analysis chapters.
With increasing global population and the
increasing proportion of old age people. Prevalence of diseases such as
Glaucoma is highly age related, the global Ophthalmology Drugs market is
expected to increase in potential and scope. TBRC’s report also covers the Ophthalmology
Drugs drivers and restraints in the market.
The global Ophthalmology Drugs market’s segment shares in
each geographic region are mentioned in the report, along with the historic and
forecast growth rates for each segment presented visually with supporting reasons
to justify the growth rates.
The top companies included in the global Ophthalmology
Drugs market report are Novartis AG, F. Hoffmann-La Roche Ltd, Allergan Plc,
Valeant Pharmaceuticals Intl Inc, Bayer AG.
About The Business Research Company:
The Business Research Company is
a Business Intelligence Company which excels in company, market and consumer
research. It has offices in the UK, the US and India and a network of trained
researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
No comments:
Post a Comment